Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome To report the toxicity and pathologic response rates ...
Low adherence to long-term adjuvant endocrine therapy in breast cancer women age 40 or younger. Background: To assess therapeutic response and treatment-related morbidity in patients treated with ...
Please provide your email address to receive an email when new articles are posted on . Talazoparib (Talzenna, Pfizer), a poly(ADP)-ribose polymerase (PARP) inhibitor, also appeared generally ...